Recent Patents on Endocrine, Metabolic & Immune Drug Discovery


Fetuin-A: A Multifunctional Protein

Author(s): Katsuhito Mori, Masanori Emoto and Masaaki Inaba

Affiliation: Metabolism, Endocrinology and Molecular Medicine Osaka City University Graduate School of Medicine 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.


Sixty-six years have elapsed since the discovery of fetuin in 1944, but its importance in mammalian physiology has only recently been appreciated. Fetuin, first isolated from fetal bovine serum and now most commonly known as either fetuin-A, alpha-2-HS-glycoprotein (recommended name by UniprotKB and PIR), or α2-Heremans-Schmid glycoprotein, functions as an important component of diverse normal and pathological processes, including vascular calcification and bone metabolism regulation, insulin resistance, protease activity control, keratinocytes migration, and breast tumor cell proliferative signaling. Fetuin-A has also been identified as a biomarker for neurodegenerative disease. Here, we summarize recent publications focusing on the structural and functional properties of fetuin-A. The emerging importance of fetuin-A for both diagnosis and therapeutics has come to the attention of the pharmaceutical industry. Therefore, we will discuss the status of patents based on fetuin-A.

Keywords: AHSG, atherosclerosis, bone metabolism, diabetes, fetuin-A, insulin resistance, vascular calcification, multiple sclerosis, Multifunctional Protein, TGF-b

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [124 - 146]
Pages: 23
DOI: 10.2174/187221411799015372